Betta Pharmaceuticals announced that in February 2020, the company's holding subsidiary exclusively authorized EyePoint to develop voronib outside the Chinese region. EyePoint released Duravyu's second key phase III Lucia data for wet age-related macular degeneration: the study did not reach the pre-set primary endpoint and failed to prove that it was statistically non-inferior compared to the abacip 2mg control group; all key secondary endpoints were achieved, and the treatment burden was significantly reduced by 38%. As of week 56, 52% of the subjects did not need supplementary treatment, and 71% of the subjects only received 0 or 1 supplemental treatment. The company is proceeding with relevant asset impairment tests, and the amount of impairment has not yet been finalized.

Betta Pharmaceuticals announced that in February 2020, the company's holding subsidiary exclusively authorized EyePoint to develop voronib outside the Chinese region. EyePoint released Duravyu's second key phase III Lucia data for wet age-related macular degeneration: the study did not reach the pre-set primary endpoint and failed to prove that it was statistically non-inferior compared to the abacip 2mg control group; all key secondary endpoints were achieved, and the treatment burden was significantly reduced by 38%. As of week 56, 52% of the subjects did not need supplementary treatment, and 71% of the subjects only received 0 or 1 supplemental treatment. The company is proceeding with relevant asset impairment tests, and the amount of impairment has not yet been finalized.